CA2269399C - Ocular devices manufactured with free radical-polymerizable latent ultra-violet absorbers - Google Patents

Ocular devices manufactured with free radical-polymerizable latent ultra-violet absorbers Download PDF

Info

Publication number
CA2269399C
CA2269399C CA2269399A CA2269399A CA2269399C CA 2269399 C CA2269399 C CA 2269399C CA 2269399 A CA2269399 A CA 2269399A CA 2269399 A CA2269399 A CA 2269399A CA 2269399 C CA2269399 C CA 2269399C
Authority
CA
Canada
Prior art keywords
absorber
acid derivatives
composition
ocular device
latent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2269399A
Other languages
French (fr)
Other versions
CA2269399A1 (en
Inventor
Frank F. Molock
Ivan M. Nunez
Laura Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Vision Care Inc
Original Assignee
Johnson and Johnson Vision Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Vision Care Inc filed Critical Johnson and Johnson Vision Care Inc
Publication of CA2269399A1 publication Critical patent/CA2269399A1/en
Application granted granted Critical
Publication of CA2269399C publication Critical patent/CA2269399C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041Lenses
    • G02B1/043Contact lenses

Abstract

The invention provides compositions for forming ocular devices which compositions contain latent UV absorbers. The compositions of the invention may be used to conveniently and efficiently produce ocular devices through UV initiated, free radical polymerization.

Description

OCULAR DEVICES MANUFACTURED WITH FREE RADICAL
POLY~~RIZABLE LATENT ULTRA-VIOLET ABSORBERS
Field of Invention s The invention relates to ocular devices containing ultra-violet absorbers.
In particular, the invention relates to compositions for producing ocular devices that contain ultra-violet absorbers. The compositions of the invention can be used to conveniently and efficiently produce ocular devices through UV initiated, free radical polymerization processes.
to Background of the Invention It is well known that ultra-violet ("UV") radiation in the 210 to 315 nanometer range may cause corneal damage. Thus, ocular devices containing UV
absorbers are desirable and methods for their production are known.
Most known UV absorbers used in ocular devices are incorporated into the polymer matrix forming the device by copoiymerization of the monomers forming the device with a functionalized form of UV absorber. The majority of commercially available ocular devices) particularly contact lenses, are manufactured using free 2o radical-polymerization processes. The most convenient method of carrying out these polymerizations is by irradiation with UV light.
Unfortunately, when UV light irradiation is used in the presence of the UV
absorber, the UV absorbing functional group or groups of the absorber interferes with curing in that the functional group competes with the W photoinitiator used in the polymerization for the incident light. The result is that the polymerization process is less efficient and may produce undercured products. Although changes in the polymerization process, such as the use of visible light initiators, may be made, these changes generally make the polymerization less efficient.
j/TiV 2f00 S~ -Thus, a need exists for a method for providing an effcient process for producing ocular devices containing W absorbers using a W initiated polymerization processes.
Detailed Description of the Invention and the Preferred Embodiments The invention provides latent W absorbers, or absorbers for use in W
initiated polymerization processes that do not interfere with the photoinitiation of the polymerization, and methods for their production. Further, the invention pro«des an efficient and convenient method for producing ocular devices containing W
1o absorbers via W initiated, free radical polymerization.
In one embodiment, the invention comprises, consists essentially of) and consists of a composition comprising at least one ocular device-forming monomer and an absorbent effective amount of a latent W absorber. In another embodiment) the invention provides a method for producing W absorber containing ocular devices comprising, consisting essentially of, and consisting of the steps of mixing an absorbent effective amount of a latent W absorber and ai least one ocular device-forming monomer to form a mixture, curing the mixture, and regenerating the latent W absorber.
In still another embodiment, the invention provides a latent W absorber comprising, consisting essentially ofy and consisting of a W absorber having at least one functional group that reacts with W light, which functional group is protected.
By "protected" is meant that the functional group is reversibly altered so that it cannot react with W light. In yet another embodiment, the invention provides a method for preparing the latent W absorber comprising, consisting essentially of, and consisting of the steps of reacting a W absorber having at least one UV
reacting functional group with a protecting agem.
By "W absorber" is meant a compound or composition capable of absorbing or screening out W radiation. By "protecting agent" is meant any compound or composition that reacts with the W absorber so as to render the W functional group or groups of the absorber substantially unreactive to W light, but that permits W initiated, free radical polymerization of the W absorber and an ocular device-forming monomer to proceed. Thus, a "latent W absorber" is a W absorber the W reacting functional group or groups of which are protected so that reaction with W light does not take place or takes place only to a minimal extent, yet which absorber can undergo W initiated polymerization with an ocular device-forming l0 monomer.
It is a discovery of the invention that free radical, W light initiated polymerization of ocular device-forming monomers and a W absorber may take place efficiently by rendering the absorber latent through the use of a protecting ~ 5 agent. Suitable W absorbers are those that may be polymerized with the monomeric materials used to form ocular devices, are known in the art, and are commercially available or methods for their making known. Generally, useful absorbers include, without limitation, benzophenones, benzotriazoles, triazines, substituted acrylonitriles, salicylic acid derivatives) benzoic acid derivatives, nickel complexes, 2o cinnamic acid derivatives, chalcone derivatives) dypnone derivatives) crotonic acid derivatives and the like, and mixtures thereof.
Examples of benzophenones include, without limitation, 2-hydroxy benzophenones such as 2-hydroxy-4-acryloxy alkoxy benzophenones, 2-hydroxy-4-z5 methacryloxy alkoxy benzophenones, allyl-2-hydroxybenzophenone, 2,4-dihydroxy benzophenone, 2-hydroxy-4-methacryloxy benzophenone, as well as 4-hydroxy, 4-methoxy, 4-octoxy, 4-decloxy, 4-dodecyloxy, 4-benzyloxy) 4,2',2'-trihydroxy and 2'-hydroxy-4,4'-dimethoxy derivatives, and the like, and mixtures thereof.

Examples of benzotriazoles include, without limitation. 2-(2'-hydroxyphenyi)benzotriazoles such as 2-(2'-hydroxyphenyl)-2H-benzotriazole and 5'-methyl, 3'S'-di-tert-butyl, 5'-( 1,1,3,3-tetramethylbutyl), 5-chloro-3',5'-di-tert-butyl, 5-chloro-3'-tertbutyl-5'-methyl, 3'-secbutyl-S'-tertbutyi, 4'-octoxy, 3' S'-di-tert-amyl, 3',5'-bis(a,a-dimethylbenryl) derivatives, 2-(2-hydroxy)-2H-benzotraizole) 2-(2-hydroxy-5-vinylphenyl)-2H-benzotriazole. 2-(2-hydroxy-S-acrylyloxyphenyl)-2H-benzotriazole, 2-(2-hydroxy-3-methacn~lamido methyl-5-tent octylphenyl) benzotriazole, and the like, and mixtures thereof.
to Additional absorbers useful in the invention are disclosed in U.S. Patent Nos.
5,133,745, 5,098,445, 4,929,250, 4,963,160, 4,868,251, 4,304,895, 4,390,676, 3,391,110, 3,365,421, 3,313,866) and 3,162,676. Preferred absorbers are benzotriazoles and benzophenones.
t5 Useful protecting agents, reactions of these agents with the UV absorber to render the absorber latent, and reaction conditions will be readily apparent to those ordinarily skilled in the art depending on the absorber selected. Generally, the protecting agent selected is one that will not participate in the polymerization of the absorber and ocular device-forming monomer other than via the polymerizable group, 2o will function as an atom source during the free radical polymerization process, and will act to quench the absorbers excited states.
For example, benzophenone absorbers may be reacted with a compound or composition, such as trimethyl orthoformate, in order to unconjugate the phenyl 25 groups so that they do not interfere with photopolymerization of the absorber and an ocular device-forming monomer. As another illustrative alternative, the C-0 group of certain of the absorbers may be reduced to the corresponding alcohol by a reducing agent, such as aluminum triisopropoxide. As yet another alternative, the ketals may be formed from absorbers containing ketone carbonyls.

The UV absorber may be mixed and polymerized with at least one ocular device-forming monomer. Such monomers are well known in the art and include, without limitation, silicon containing monomers, hydroxy alkyl esters of polymerizable unsaturated acids, such as acrylic) methacryiic, fumaric) and malefic s acids, alkyl and cycloalkyl acrylates and methacrylates, noncyclic amides, heterocyclic N-vinyl lactarrrs, aminoalkyl esters of unsaturated acids, mercapto alkyl esters of unsaturated acids, styryl monomers) and the like. Preferred monomers include methyl methacrylate, hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, ethyl acrylate, butyl acrylate, styryl monomers, N-vinyl pyrrolidone) and mixtures thereof.
io More preferred monomers are hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, methyl methacrylate and mixtures thereof.
Generally the latent W absorber is present in an absorbent effective amount, which is an amount sufficient to absorb, once the latent absorber is regenerated, a 15 substantial portion, at least about 80 percent, of the W light in the range of from about 280 to about 370 run that impinges on the ocular device formed. One ordinarily skilled in the art will recognize that the specific amount of absorber used will depend on the molecular weight of the absorber and its extinction coefficient in the about 280 to about 3 70 nm range. Typically, about 0.5 percent to about 5.0 2o percent, preferably about 0.5 percent to about 3 .0 percent, by weight of the monomer mixture is used.
Although polymerization may be carried out by any known method, the invention will most beneficially be used in IJV initiated, free radical polymerizations.
25 These processes and conditions for carrying them out are well known to those ordinarily skilled in the art.
Typically, the W polymerization is carried out in the presence of a photoinitiator which photoirritiators are well known and commercially available.
3o Illustrative W initiators include, without limitation, 2-hydroxy-2-methyl propiophenone, ( I-hydroxycyclohexyl) phenyl ketone) and 2,2-dimethoxy-2-phenyl acetophenone, DAROCURETM 1173, IRGACURETM 184, and IRGACURE'r'M 651, respectively all available from CIBA-Geigy.
In addition to a photoinitiator, it may be desirable to include other additives to the mixture top be cured. Suitable additives include, without limitation, dyes, stabilizers, diluents, surfactants, crosslinkers, and the tike.
Preferably, the mixture of latent absorber. monomer, and other additives is 1 o formed and cured so as to form a contact lens. :Methods for forming contact lenses are well known and include, without limitation, spin casting) mold casting, and the like.
After curing is completed to the desirable degree, the latent absorber undergoes regeneration or restoration of its W functional groups. 'fhe conditions for regeneration will depend on the protecting agent and absorber used. For example, in cases in which a reducing agent is used to convert the C~ groups of a benzophenone to C-OH groups, regeneration may be carried out by contacting the cured compound with a slightly alkaline) 1 percent potassium permanganate solution, or another mild oxidizing agent, for several minutes. As another example, air may be used to regenerate the LJV functional groups in some cases.
The invention may be most useful for forming ocular devices, such as spectacle lenses, contact lenses, intraocular lenses, and the like. However, it will be recognized that the invention is suitable for application to other polymeric substrates in which W absorbing characteristics are desirable, such as films, solar energy collectors, polymeric coatings and films, 9uoresoent light diffusers, packaging materials, vinyl window coverings, automobile pails, fiberglass constructions, and the like.

The invention will be clarified further by a consideration of the following non-linliting examples.
Examples Example 1 75 g of 3,3,4,4-benzophenone tetracarboxylic di:.nltydride (0.343 moles) were dissolved in 225 mL anhydrous pyridine, the pyridine (less than 0.05 % water).
The mixture was added to a 1 L jacketed, three-necked, round bottomed flask equipped with a drying tube filled with CaSO, a magnetic stirring bar, and a 250 mL
addition 1o funnel. The circulating fluid was set at 20° C and a solution of 60.2 g 2-hydroxyethyl methacrylate ("HEMA") (0.463 moles), 3.45 g 4-pyrrolidino pyridine (23.7 moles), and 65 g anhydrous pyridine were added dropwise with rapid stirring to the contents of the round bottomed flask. The addition took place over a 3 hr period. The round bottomed flask contents were allowed to stir at 20° C for an additional 16 hrs. At that point, the anhydride groups were found to be completely reacted as indicated by the absence of the anhydride carbonyl absorption band from the IR spectra of the crude mixture.
The crude reaction mixture was transferred to a 2 L jacketed, three necked, 2o round bottomed flask equipped with a mechanical stirrer, a drying tube filled with CaSO,, and a stopper on the third neck. 96.1 g 1,3-dicyclohexyl dicarbodiimide (0.466 moles) were added directly to the contents of the round bottomed flask via a powder fiuutel and dissolved by stirring at 20° C for 1.5 hrs. The circulating fluid temperature was then lowered to 0° C and 22.7 g dry ethanol (less than 0.063 water) (0.493 moles) were added dropwise over a period of 1 hr via a 60 mL
addition funnel. After the addition was completed, the funnel was rinsed with approximately 20 mL pyridine and the circulating fluid temperature was set at 20° C
at which point the crude reaction mixture became deep red. The reaction proceeded for another hrs after which the pyridine was removed under reduced pressure in a rotary 3o evaporator to yield 156.6 g cnui~ product. The crude product was dissolved in 225 g ethyl acetate and washed twice with equal volumes of 5% aqueous HC1 (resulting in an emulsion that was broken up with NaCI) and) subsequently, with equal volumes of deionized water. The organic layer was dried over anhydrous MgS04, filtered and the solvent removed under reduced pressure in a rotary evaporator to yield 110.9 g viscous, clear-orange oil.
59.1 g (0.086 mol (est.)) of the product was then poured into a 2 L round bottomed flask equipped with a magnetic stirring bar. 3 SO g anhydrous acetonitrile (less than 0.005 percent water) were added to the flask and allowed to dissolve the to product. 120 g montmorillonite K-10 clay were charged to the flask via a powder funnel and) subsequently, 180 mL trimethyl orthoformate were poured into the flask.
The resulting slurry was allowed to stir at room temperature under a dry nitrogen atmosphere for 48 hrs. The solvent was then removed under pressure in a rotary evaporator to yield 26 g (44% yield) of a clear, viscous oil.
Example 2 228 g dry 2-propanol (less than 0.005 % water), 75 g toluene (less than 0.005 water) , and 25 g 4-methacryloxy-2-hydroxybenzophenone (88.7 mmol) were charged into a 500 mL, three necked, jacketed, round bottomed flask equipped with a 2o Friedrich condenser capped with a drying tube filled with indicating CaSO, a thermometer, a magnetic stirrer, and a glass stopper. The temperature of the circulating fluid to the condenser was set a 5° C. The contents of the flask were allowed to stir for a few minutes and 18 g aluminum triisopropoxide (88.2 mmol) were added to the reaction flask via a powder funnel. Residue of the aluminum isopropoxide on the fiumel was washed into the flask with 38 g dry 2-propanol.
The circulating fluid to the reaction was set at 65° C. The reaction was then followed by the appearance of a very intense OH band in the IR spectra centered at 3350 cm 1 as well as disappearance of UV absorption above 250 nm.

The reaction was deemed complete after ?4 hrs at which point the reaction mixture was allowed to cool to room temperature and the solvent was removed.
To the resulting yellow oil was added 200 mL 2.5 14t HCl (aq. ) and the resulting mixture was stirred in a rotary evaporator for 1 hr at ambient temperature and pressure. The insoluble, yellow solid that resulted was re-dissolved in toluene and mixed with leftover liquid material. The toluene solution was washed with deioniied water , dried over MgSO,, filtered, and the solvent removed under reduced pressure.
The viscous, yellow oil ( I 2.9 g, 51 % yield based on starting 4-methacryloxy-2-hydroxybenzophenone) exhibited IR and UV spectra consistent with the loss of the 1o benzophenone functional group.
Examples 1 and 2 illustrate alternative methods for producing a latent UV
absorber using a benzophenone absorber.
Example 3 A reactive monomer mixture of 0.8 wt percent ethylene glycol dimethacrylate, 0.4 wt percent DAROCUR'"'~ I 173, 2 wt percent methacrylic acid, and 96.8 wt percent HEMA were blended with enough diluetrt to make up a 48 percent monomer/52 percent diluent mix. The diluent was a 50:50 by wt mixture of 2o PHOTONOL~ 7025 ( an 8 mole ethoxylate of bisphenol A) and GLUCAMT'~ E-20 a 20 mole ethoxylate of methyl glucose). This mixture constituted the control, or _-~.-zero UV Mocker concentration sample.
After thoroughly mixing the above blend at 65° C, the mixture was allowed to stir under reduced pressure, 40 mm HG, for 30 min at 65° C and then transferred to two-piece, polystyrene) contact lens molds. The filled molds were exposed to 380 nm UV light (I.5-2.0 Jouleslcm2 dose) for 30 min. at room temperature. The __ molds were then separated and placed in physiological saline solution for 3 hrs at 70°
C to remove the inert diluent aad any residual, u~eacted monomer. After the initial leaching pe~od, the lenses were allowed to equilibrate to room temperature in a fresh bath of physiological saline.
Example 4 A reactive monomer mixture was prepared as in Example 3, except that 1 wt percent of the reduced 4-hydroxy benzophenone of Example 2 and 95.8 wt percent of HEMA were used. T'he mixture was blended, molded, and cured as in Example 3.
Example 5 1o A reactive monomer mixture was prepared as in Example 3, except that 5 wt percent of the reduced 4-hydroxy benzophenone Example 2 and 91.8 wt percent of HEMA were used. The mixture was blended, molded, and cured as in Example 3.
Example 6 The lenses prepared in Examples 4 and 5 were exposed to a slightly alkaline (pH = 8.0) borate buffer) 1 % potassium permanganate solution. Testing for regeneration was carried out by running a spectrum from 200 nm to 500 nm and comparing the W absorbance compared to lenses without W absorbers. The results showed that good absorbance of the lenses of Examples 4 and 5 and, thus, 2o that, as a result of exposure to the solution) the benzophenone group was regenerated.

Claims (20)

1. A composition comprising at least one ocular device-forming monomer and an absorbent effective amount of a latent UV absorber.
2. The composition of claim 1 wherein the ocular device forming-monomer is selected from the group consisting of methyl methacrylate, hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, ethyl acrylate, butyl acrylate, styryl monomers, N-vinyl pyrrolidone, and mixtures thereof.
3. The composition of claim 1 wherein the ocular device-forming monomer is hydroxyethyl methacrylate.
4. The composition of claim 1 wherein the ocular device-forming monomer is ethyleneglycol dimethacrylate.
5. The composition of claim 1 wherein the ocular device-forming monomer is methyl methacrylate.
6. The composition of claim 1 wherein the absorber is selected from the group consisting of benzophenones, benzotriazoles, triazines, substituted acrylonitriles, salicylic acid derivatives, benzoic acid derivatives, nickel complexes, cinnamic acid derivatives, chalcone derivatives, dypnone derivatives, crotonic acid derivatives and mixtures thereof.
7. The composition of claim 1 wherein the absorber is a 2-hydroxy benzophenone.
8. The composition of claim 1 wherein the absorber is a benzotriazole.
9. A composition comprising at least one ocular device-forming monomer selected from the group consisting of methyl methacrylate, hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, ethyl acrylate, butyl acrylate, styryl monomers, N-vinyl pyrrolidone, and mixtures thereof and a latent UV absorber selected from the group consisting of benzophenones and benzotriazoles,, wherein the absorber is present in an amount of from about 0.5 to about 5.0 percent by weight of the monomer mixture.
10. The composition of claim 9 wherein the absorber is a 2-hydroxy benzophenone.
11. A method for forming a UV absorber containing ocular device comprising the steps of:
mixing a latent UV absorber and at least one ocular device forming-monomer, curing the mixture; and regenerating the latent UV absorber in the cured mixture to produce a UV
absorber containing ocular device.
12. The method of claim 11 wherein the ocular device-forming monomer is selected from the group consisting of methyl methacrylate, hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, ethyl acrylate, butyl acrylate, styryl monomers, N-vinyl pyrrolidone, and mixtures thereof; the latent UV absorber is selected from the group consisting of benzophenones and benzotriazoles, and wherein the absorber is present in an amount of from about 0.5 to about 5.0 percent by weight of the monomer mixture.
13. The method of claim 11 wherein the UV absorber containing ocular device is a contact lens.
14. The method of claim 12 wherein the UV absorber containing ocular device is a contact lens.
15. The method of claim 12 wherein the UV absorber is a 2-hydroxy benzophenone.
16. A latent UV absorber comprising a UV absorber having at least one functional group reactive with UV light wherein the at least one functional group is protected.
17. The absorber of claim 16 wherein the UV absorber is selected from the group consisting of benzophenones, benzotriazoles, triazines, substituted acrylonitriles, salicylic acid derivatives, benzoic acid derivatives, nickel complexes, cinnamic acid derivatives, chalcone derivatives, dypnone derivatives, crotonic acid derivatives and mixtures thereof.
18. The absorber of composition of claim 16 wherein the absorber is a 2-hydroxy benzophenone.
19. A method for preparing the latent UV absorber of claim 16 comprising the steps of reacting a UV absorber having at least one functional group reactive with UV light with a protecting agent.
20. The method of claim 19 wherein the UV absorber is selected from the group consisting of benzophenones, benzotriazoles, triazines, substituted acrylonitriles, salicylic acid derivatives, benzoic acid derivatives, nickel complexes, cinnamic acid derivatives, chalcone derivatives, dypnone derivatives, crotonic acid derivatives and mixtures thereof.
CA2269399A 1998-04-20 1999-04-19 Ocular devices manufactured with free radical-polymerizable latent ultra-violet absorbers Expired - Lifetime CA2269399C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/063,625 US6218463B1 (en) 1998-04-20 1998-04-20 Ocular devices manufactured with free radical-polymerizable latent ultra-violet absorbers
US09/063,625 1998-04-20

Publications (2)

Publication Number Publication Date
CA2269399A1 CA2269399A1 (en) 1999-10-20
CA2269399C true CA2269399C (en) 2010-08-31

Family

ID=22050446

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2269399A Expired - Lifetime CA2269399C (en) 1998-04-20 1999-04-19 Ocular devices manufactured with free radical-polymerizable latent ultra-violet absorbers

Country Status (12)

Country Link
US (1) US6218463B1 (en)
EP (2) EP0952467B1 (en)
JP (1) JP4361163B2 (en)
KR (1) KR19990083308A (en)
CN (1) CN1124315C (en)
AR (1) AR015772A1 (en)
AU (1) AU761959B2 (en)
BR (1) BR9901393B1 (en)
CA (1) CA2269399C (en)
DE (1) DE69926565T2 (en)
SG (1) SG85636A1 (en)
TW (1) TWI228136B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760261A (en) * 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5945465A (en) * 1998-05-15 1999-08-31 Bausch & Lomb Incorporated Method for polymerizing contact lenses having UV absorbing properties
JP3676138B2 (en) * 1999-09-20 2005-07-27 Hoya株式会社 Plastic spectacle lens excellent in ultraviolet absorption and manufacturing method thereof
JP3547662B2 (en) 1999-09-20 2004-07-28 Hoya株式会社 Plastic spectacle lens excellent in ultraviolet absorption and method of manufacturing the same
US20050148570A1 (en) * 2001-11-08 2005-07-07 Liren Huang Novel substituted alkane compounds and uses thereof
EP1453913A4 (en) * 2001-11-08 2006-04-05 Antex Pharma Inc Novel substituted alkane compounds and uses thereof
US7237893B2 (en) * 2001-12-28 2007-07-03 Chang Shiao H Light adjustable lenses capable of post-fabrication power modification via multi-photon processes
US6851804B2 (en) * 2001-12-28 2005-02-08 Jagdish M. Jethmalani Readjustable optical elements
US7560499B2 (en) * 2001-12-28 2009-07-14 Calhoun Vision, Inc. Initiator and ultraviolet absorber blends for changing lens power by ultraviolet light
EP1348575A1 (en) 2002-03-27 2003-10-01 Landqart Security paper and other security items
AU2003297108B2 (en) 2003-01-09 2008-01-10 Alcon, Inc. Dual function UV-absorbers for ophthalmic lens materials
US7354980B1 (en) 2004-03-12 2008-04-08 Key Medical Technologies, Inc. High refractive index polymers for ophthalmic applications
US7446157B2 (en) 2004-12-07 2008-11-04 Key Medical Technologies, Inc. Nanohybrid polymers for ophthalmic applications
WO2010071691A1 (en) * 2008-12-18 2010-06-24 Novartis Ag Method for making silicone hydrogel contact lenses
MY151232A (en) * 2008-12-30 2014-04-30 Novartis Ag Tri-functional uv-absorbing compounds and use thereof
BR112012005626A2 (en) * 2009-09-15 2016-08-02 Novartis Ag Suitable prepolymers for making ultraviolet absorption contact lenses
JP5784119B2 (en) 2010-07-30 2015-09-24 ノバルティス アーゲー Amphiphilic polysiloxane prepolymers and their use
WO2012047961A1 (en) 2010-10-06 2012-04-12 Novartis Ag Polymerizable chain-extended polysiloxanes with pendant hydrophilic groups
EP2625218B1 (en) 2010-10-06 2018-04-25 Novartis AG Water-processable silicone-containing prepolymers and uses thereof
US8835525B2 (en) 2010-10-06 2014-09-16 Novartis Ag Chain-extended polysiloxane crosslinkers with dangling hydrophilic polymer chains
US8899745B2 (en) 2010-12-13 2014-12-02 Novartis Ag Ophthalmic lenses modified with functional groups and methods of making thereof
US8475975B2 (en) * 2011-06-21 2013-07-02 General Electric Company Method of recording data in an optical data storage medium and an optical data storage medium

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391110A (en) 1961-08-21 1968-07-02 American Cyanamid Co Polymerizable benzophenone uv absorber-condensation polymers
US3313866A (en) 1965-10-11 1967-04-11 American Cyanamid Co Light-stabilized composition of resin and 2-hydroxy-4-acryloxyethoxybenzophenones and homopolymers thereof
US3365421A (en) 1965-10-11 1968-01-23 American Cyanamid Co 2-hydroxy-4-acryloxyethoxybenzophenones and homopolymers thereof
US4304895A (en) 1973-06-20 1981-12-08 Wesley-Jessen, Inc. Ultraviolet absorbing corneal contact lenses
US4175945A (en) * 1976-02-19 1979-11-27 Rohm And Haas Company Benzophenones and benzhydrols
US4390676A (en) 1976-11-15 1983-06-28 Schering Corporation Ultraviolet absorbing lenses
US4302435A (en) * 1980-09-22 1981-11-24 E. I. Du Pont De Nemours And Company Hydrogenation of a diarylketone to a diarylmethanol
US4528311A (en) 1983-07-11 1985-07-09 Iolab Corporation Ultraviolet absorbing polymers comprising 2-hydroxy-5-acrylyloxyphenyl-2H-benzotriazoles
JPS60166327A (en) 1984-02-09 1985-08-29 Toshiba Silicone Co Ltd Production of novel copolymer
US4520074A (en) 1984-07-20 1985-05-28 General Electric Company Polymerizable 3-aroyloxyphenyl carbamates and methods for their preparation and use
EP0180548B1 (en) * 1984-11-01 1989-06-28 Ciba-Geigy Ag Coatings stabilized against the action of light
ATE127592T1 (en) * 1984-12-18 1995-09-15 Tr Dev Ltd HYDROGEL-FORMING POLYMERS.
US5135965A (en) 1984-12-18 1992-08-04 T. R. Developments, Ltd. Hydrogel-forming polymers used in intraocular lenses
US5141990A (en) 1985-06-07 1992-08-25 California Institute Of Technology Photocurable acrylic composition, and U.V. curing with development of U.V. absorber
US4719248A (en) 1985-08-08 1988-01-12 Bausch & Lomb Incorporated Ultraviolet blocking agents for contact lenses
US4868251A (en) 1986-12-24 1989-09-19 Allergan, Inc. Ultraviolet light absorbing silicone compositions
US5133745A (en) 1988-05-26 1992-07-28 Alcon Laboratories, Inc. Ultraviolet absorbing hydrogels
US4963160A (en) 1989-03-14 1990-10-16 Ciba-Geigy Corporation Reactive uv absorbing compositions and method of preparing lenses therefrom
US4929250A (en) 1989-03-14 1990-05-29 Ciba-Geigy Corporation Ultraviolet absorbing lenses and method of making the same
US5663212A (en) 1993-02-05 1997-09-02 Fuji Photo Film Co., Ltd. Light-sensitive resin composition
GB2278133B (en) * 1993-05-21 1996-09-04 Yamada Chem Co Recording material
JPH0718245A (en) * 1993-06-30 1995-01-20 Nippon Paint Co Ltd Ultraviolet absorber composition, ultraviolet-curing resin composition containing the same absorber composition and curing of the same resin composition
EP0711804A3 (en) * 1994-11-14 1999-09-22 Ciba SC Holding AG Latent light stabilizers

Also Published As

Publication number Publication date
SG85636A1 (en) 2002-01-15
AU761959B2 (en) 2003-06-12
JPH11337885A (en) 1999-12-10
EP0952467B1 (en) 2005-08-10
JP4361163B2 (en) 2009-11-11
BR9901393A (en) 2000-05-23
AR015772A1 (en) 2001-05-16
CN1233630A (en) 1999-11-03
TWI228136B (en) 2005-02-21
BR9901393B1 (en) 2011-01-11
EP1584952A1 (en) 2005-10-12
DE69926565T2 (en) 2006-06-08
US6218463B1 (en) 2001-04-17
AU2380999A (en) 1999-10-28
CA2269399A1 (en) 1999-10-20
EP0952467A1 (en) 1999-10-27
CN1124315C (en) 2003-10-15
DE69926565D1 (en) 2005-09-15
KR19990083308A (en) 1999-11-25

Similar Documents

Publication Publication Date Title
CA2269399C (en) Ocular devices manufactured with free radical-polymerizable latent ultra-violet absorbers
JP3894984B2 (en) Manufacturing method of UV absorbing contact lens
EP1088246B1 (en) Method for preparing lenses having UV-absorbing properties
AU751052B2 (en) Method for making contact lenses having UV absorbing properties
JP2858953B2 (en) UV absorbing benzotriazole having styrene group
JP3676138B2 (en) Plastic spectacle lens excellent in ultraviolet absorption and manufacturing method thereof
KR100841870B1 (en) Plastic lens with excellent ultraviolet absorption and process for producing the same
KR20010043474A (en) Method for polymerizing contact lenses
JPS6021631B2 (en) Photochromic composition and its manufacturing method
EP0549808A1 (en) Transparent plastic material
JP3957592B2 (en) Methacrylic resin and its use
JPH0353329B2 (en)
JP2003105033A (en) Monomer composition for optical material and cured product
JPS59184227A (en) Film-forming composition and surface modification of synthetic resin molding by using same
KR101110843B1 (en) Block copolymer resin having anti-fogging property and composition comprising the same for anti-fogging coating with excellent weatherability
JP3641079B2 (en) UV absorber
JPS59193924A (en) Composition for optical material
JPH0570524A (en) Optical resin
JP3981602B2 (en) Radical polymerizable sulfur-containing adamantane compound and cured product
JP2002156502A (en) Monomer composition for optical material and cured body
JPS61190507A (en) Medical material
JPH10228004A (en) Plastic spectacle lens
JPH01257819A (en) Method of dyeing plastic lens for spectacles
MXPA00011034A (en) Method for polymerizing contact lenses having uv absorbing properties

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190423